BiotechTube

Halobetasol Topical Foam

ApprovedCompleted
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Plaque Psoriasis

Conditions

Plaque Psoriasis

Trial Timeline

Jun 14, 2019 → Dec 30, 2019

NCT ID
NCT03992261

About Halobetasol Topical Foam

Halobetasol Topical Foam is a approved stage product being developed by Mayne Pharma Group for Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03992261. Target conditions include Plaque Psoriasis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03992261ApprovedCompleted

Competing Products

20 competing products in Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
CT-P55 + EU-approved CosentyxCelltrionPhase 3
77
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
alefaceptAstellas PharmaApproved
85
AlefaceptAstellas PharmaApproved
85
Halobetasol PropionateSun PharmaceuticalPhase 2
52
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
DSXS + PlaceboSun PharmaceuticalPhase 3
77
DSXSSun PharmaceuticalPhase 2
52
DSXS topicalSun PharmaceuticalPhase 2
52
Halobetasol Topical LotionSun PharmaceuticalApproved
85
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Matching PlaceboSun PharmaceuticalPhase 3
77
DSXS1411 + PlaceboSun PharmaceuticalPhase 2
52
Tildrakizumab + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Tildrakizumab Placebo + Etanercept Placebo + Etanercept 50 mgSun PharmaceuticalPhase 3
77
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
77

Other Products from Mayne Pharma Group

Sporanox + LozanocApproved
77
Doxycycline Hyclate Delayed-Release 200 mgApproved
77
Slow release oral morphine (SROM) + MethadonePhase 3
69
Permethrin Cream, 5% + ElimitePhase 3
69
Ivermectin 0.5% Topical Application Lotion + Ivermectin 0.5% Topical Application Lotion [SKLICE] + Placebo 0% LotionPhase 3
69